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Abstract
Background: A polymorphism in the transcription factor 7-like 2 (TCF7L2) gene has been found to be associated with
type 2 diabetes in case-control studies. We aimed to estimate associations of the marker rs7903146 (C/T) polymorphism
with fasting glucose, lipids, diabetes prevalence and complications in an older general population.
Methods: In total, 944 subjects aged ≥ 65 years from the population representative InCHIANTI study were enrolled in
this study. Those with fasting blood glucose of ≥ 7 mmol/l or physician diagnosis were considered diabetic. Cut-off points
for impaired fasting glucose (IFG) were ≥ 5.6 mmol/l to < 7 mmol/l.
Results: In the general population sample, minor (T) allele carriers of rs7903146 had higher fasting blood glucose (FBG)
(p = 0.028) but lower fasting insulin (p = 0.030) and HOMA2b scores (p = 0.001), suggesting poorer beta-cell function.
T allele carriers also had smaller waist circumference (p = 0.009), lower triglyceride levels (p = 0.006), and higher high-
density lipoprotein cholesterol (p = 0.008).
The prevalence of diabetes or IFG was 32.4% in TT carriers and 23.3% in CC carriers; adjusted OR = 1.67 (95%
confidence interval 1.05 to 2.65, p = 0.031). Within the diabetic and IFG groups, fewer T allele carriers had metabolic
syndrome features (p = 0.047) or had experienced a myocardial infarction (p = 0.037). Conversely, T allele carriers with
diabetes had poorer renal function (reduced 24-hour creatinine clearance, p = 0.013), and possibly more retinopathy (p
= 0.067). Physician-diagnosed dementia was more common in the T carriers (in diabetes p = 0.05, with IFG p = 0.024).
Conclusion: The TCF7L2 rs7903146 polymorphism is associated with lower insulin levels, smaller waist circumference,
and lower risk lipid profiles in the general elderly population. Patients with diabetes who are carriers of the minor allele
are less likely to have metabolic-syndrome features, but may experience more microvascular complications, although the
number of cases was small. If replicated, these findings may have implications for developing treatment approaches
tailored by genotype.
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Introduction
Type 2 diabetes mellitus is an important disabling condi-
tion[1], and its prevalence is increasing. Type 2 diabetes
mellitus is generally understood to be a metabolic disor-
der defined by hyperglycemia and insulin resistance com-
bined with abdominal obesity, dyslipidemia and
hypertension. The current focus of management of diabe-
tes mellitus has moved from controlling hyperglycemia
alone to a multifactorial approach to risk reduction[2,3].
An association has recently been established between type
2 diabetes and variation in the transcription factor
TCF7L2 gene in a large Icelandic study[4]. Two additional
cohorts showed similar associations, giving a combined
odds ratio (OR) = 1.56, 95% confidence interval (CI) 1.41
to 1.73, p = 4.7 × 10-18 per allele. The rs7903146 single
nucleotide polymorphism (SNP) in TCF7L2 is in linkage
disequilibrium with the risk microsatellite, and has been
recommended for use in replication studies[4]. In a sepa-
rate study of progression to diabetes in the Diabetes Pre-
vention Program, Florez et al[5] found that the same
variant in TCF7L2 was associated with an increased risk of
diabetes incidence among people with impaired glucose
tolerance. Several case-control studies have now repli-
cated these findings [6-11].
Thus far, the available evidence for TCF7L2 has been from
case-control comparisons or intervention trial volunteers,
and not representative general populations; data from eld-
erly populations, in whom risks of type 2 diabetes are
highest, are scarce. As Sackett and Haynes[12] have
pointed out, many biomarkers have appeared promising
in comparisons of clear-cut cases and controls, only to
perform poorly in the general population. In maturity
onset diabetes of the young, the clinical presentation and
treatment needs of patients varies markedly by geno-
type[13]; whether such clinical heterogeneity by genotype
is present for TCF7L2 and type 2 diabetes is unclear.
Our study aimed to investigate whether the presentation
of diabetes and related features is associated with TCF7L2
genotype in a representative population of older people.
We genotyped the TCF7L2 SNP rs7903146, and correlated
genotype with diabetes-related biochemical changes and
measures of diabetes complications.
Methods
The data were from the InCHIANTI Study[14] of aging, a
representative sample of 1155 people aged ≥ 65 years in
two towns in Tuscany, Italy. Subjects had an initial assess-
ment at home followed by two clinic visits between Sep-
tember 1998 and March 2000. The participants were all of
white European origin. The Italian National Institute of
Research and Care of Aging Institutional Review Board
approved the study.
The InCHIANTI cohort has been studied extensively for
phenotypic measures of aging, including biochemical and
physical tests. We analyzed data on fasting plasma glucose
and insulin levels, and calculated Homeostasis Model
Assessment (HOMA2) scores using a formula from the
Oxford Centre for Diabetes, Endocrinology and Metabo-
lism (http://www.dtu.ox.ac.uk, accessed June 2006). Fast-
ing insulin was determined using a commercial double-
antibody, solid-phase radioimmunoassay (Sorin Biomed-
ica, Milan, Italy) with an intra-assay coefficient of
3.1%[15]. Fasting blood glucose was determined by an
enzymatic colorimetric assay using a modified glucose
oxidase-peroxidase method (Roche Diagnostics GmbH,
Mannheim, Germany) and a Roche-Hitachi 917 analyzer.
Diseases were ascertained by an experienced clinician
using pre-established criteria combining self-reported
physician diagnoses, current pharmacologic treatment,
medical records, clinical examinations, and blood
tests[16]. The "diabetes" group in this analysis had fasting
blood glucose levels of ≥ 7.0 mmol/l or a physician diag-
nosis of diabetes with diabetes diet or drug treatment in
the previous 2 weeks. Impaired fasting glucose was
defined according to American Diabetes Association
(ADA) criteria[17,18] as a fasting glucose of 5.6–6.9
mmol/L, excluding cases diagnosed as diabetic.
A 24-hour urine collection was performed, and urinary
and serum creatinine were measured using a modified
Jaffe method. A creatinine clearance of ≤ 30 mL/min was
considered renal insufficiency, a threshold previously
shown to be associated with anemia in older people in
this dataset[19]. For metabolic syndrome, measures were
dichotomized in accordance with the Adult Treatment
Panel III (ATP III) definitional criteria[20]: men are classi-
fied ashaving abdominal obesity if their waist circumfer-
ence is > 1020 mm, women if their waist circumferenceis
> 880 mm. For both sexes a high triglyceride level was
considered to be ≥ 150 mg/dL. Men were classified as hav-
ing low high-density lipoprotein (HDL) levels if the
serum level was ≤ 40 mg/dL; for women the cut-point was
≤ 50 mg/dL.
Genotyping
The rs7903146 SNP was genotyped using a TaqMan PCR
assay: 20 ng of genomic DNA was amplified in each assay
in the presence of specific probes for each SNP variant
labeled with fluorescent dye at the 5' end and a quencher
molecule at the 3' end (designed by Applied Biosystems'
"assays-by-design" service). PCR was carried out in 1 μl
reaction volumes with 1× ABsolute™QPCR mix (ABgene)
and 1× probe mix (Applied Biosystems). An initial dena-
turation at 95°C for 10 minutes was followed by 40 cycles
of PCR, with 15 seconds denaturation at 95°C, and 1
minute annealing/extension at 60°C. Following 40 cyclesBMC Medicine 2006, 4:34 http://www.biomedcentral.com/1741-7015/4/34
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of PCR, fluorescence was measured for each probe on a
Pherastar plate reader and compared with an internal con-
trol ROX dye standard. Genotypes were assigned using
Klustercaller software (Kbioscience™). A percentage
(10%) of samples was duplicated and scored blind.
Statistics
Linear regression models used log-transformed values of
all serum levels, adjusted for age and sex. The distribution
of insulin and insulin2 (in pmol/mL) were not normally
distributed on skewness and kurtosis normality testing (p
< 0.0001 for both). Transforming to log(insulin) and
log(insulin2) yielded normality test p  values of 0.0085
and 0.6438 respectively; we therefore used log(insulin2)
in linear models, which assume normal distributions.
Logistic regression models were used for the age- and sex-
adjusted categorical associations. Type 2 diabetes is more
common in men, but in the adjusted models, sex did not
reach significance, and therefore all analysis was per-
formed with both sexes together.
Results
Characteristics of subjects
There were 944 subjects for whom DNA available and
genotyped for TCF7L2 (Table 1) aged ≥ 65 years. In this
general population sample, the mean age was 75 years
(range 65–102). The proportion in the obese category
(BMI ≥ 30) was 32% in the whole sample and 41% in the
group with diabetes. Similar differences were evident on
abdominal obesity (with sex-specific waist measure-
ments).
The frequencies of each genotype in the whole sample
were similar to published data (Table 1). There were no
inconsistencies among the duplicate samples and no sig-
nificant deviation from Hardy-Weinberg equilibrium (σ2
= 0.012, p = 0.912).
Effect of TCF7L2 in the general elderly population sample
In the general elderly population sample, there was a sig-
nificant trend toward higher fasting glucose levels with
increasing number of T alleles (mean fasting glucose 5.31
mmol/L in the TT group, 5.19 mmol/L in the CT group,
and 5.08 mmol/L in the CC group; age and sex adjusted
per allele regression model p = 0.028) (Table 2). Logged
fasting insulin2 levels were significantly lower in the T
allele groups and there was also a strong trend per T allele
of reduction in HOMA2b measures, suggesting impaired
beta-cell function (96% in TT versus 113% in CC group,
regression p = 0.001). HOMA2S-measured insulin sensi-
tivity increased with increasing number of T alleles but
this did not reach formal significance. However, upon
removing patients who were on drug treatment, the asso-
Table 1: Characteristics of the InCHIANTI study general population sample aged ≥ 65 years, and the subgroup with diabetes
All subjects ≥ 65 years Subjects with diabetes
Number of subjects 944 127
Male 415 (44%) 64 (50%)
Age (years) 75 ± 7.4 74 ± 6.8
BMI
< 25 kg/m2 251 (27%) 23 (18%)
25–29 kg/m2 395 (42%) 52 (41%)
30+ kg/m2 298 (32%) 52 (41%)
Subjects with abdominal obesity* 343 (40%) 60 (47%)
Fasting glucose levels
< 6 mmol/L 774 (82%) 31 (24%)
6–6.9 mmol/L 70 (7%) 18 (14%)
7+ mmol/L 100 (11%) 78 (61%)
Insulin levels (pmol/L) 68.6 ± 1.7 76.3 ± 1.7
HOMA beta cell function (%) 107.7 ± 1.6 59.6 ± 1.9
HOMA insulin sensitivity (%) 75.9 ± 1.6 62.7 ± 1.6
Total cholesterol (mg/dL) 213.1 ± 1.2 205.3 ± 1.2
LDL (mg/dL) 131.2 ± 1.3 124.7 ± 1.3
HDL (mg/dL) 53.7 ± 1.3 49.2 ± 1.3
Triglycerides (mg/dL) 114.1 ± 1.6 124.7 ± 1.7
rs7903146 genotypes
CC 394 (42%) 49 (39%)
CT 439 (47%) 57 (45%)
TT 111 (12%) 21 (17%)
* Men were classified as being abdominally obese if their waist circumference was more than 1020 mcm, women if their waist circumference was 
more than 880 mm.
Data are n (%) or mean ± SD.BMC Medicine 2006, 4:34 http://www.biomedcentral.com/1741-7015/4/34
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ciation with HOMA2S was significant (β = 0.057, 95% CI
0.006 to 0.108, p = 0.027).
In addition to the glucose/insulin axis changes, there were
also changes in lipid levels, with the T allele being associ-
ated with significantly higher levels of HDL cholesterol (p
= 0.008 in the per allele model) and lower levels of triglyc-
erides (p = 0.006 in per allele model), suggesting a lower
risk lipid profile. These associations were independent of
the marginal association with insulin sensitivity: on
adjusting for logged HOMA2ir values, both the triglycer-
ide (per allele β = -0.0568, 95% CI -0.101 to -0.0125, p =
0.012) and HDL associations (per allele β = 0.030, 95% CI
0.003 to 0.053, p = 0.027) remained.
When subjects with diabetes or impaired fasting glucose
were excluded from the models in Table 2, serum levels of
HDL and triglycerides remained associated with the
rs7903146 genotype (per allele β = 0.037, 95% CI 0.009
to 0.066, p = 0.010 and β = -0.058, 95% CI -0.107 to -
0.009, p = 0.021 respectively). None of the other measures
in Table 2 was significant after removal of the diabetic and
impaired fasting glucose (IFG) groups.
Table 2: Serum levels by genotype in the whole InCHIANTI population aged ≥ 65 years, with age- and sex-adjusted linear regression 
model estimates of associations with logs of measures
Model: age and sex adjusted, for log of measure
n Mean SD Beta SE p value
Glucose (mmol/L) CC 379 5.08 1.22 0
CT 432 5.19 1.23 0.024 0.015 0.100
TT 109 5.31 1.27 0.044 0.022 0.052
Per minor allele 0.022 0.010 0.028
Insulin2 CC 364 81.74 1.69 0
pmol CT 416 78.87 1.70 -0.038 0.035 0.276
TT 103 70.48 1.55 -0.121 0.054 0.026
Per minor allele -0.053 0.025 0.030
HOMA beta cell function (%) CC 362 113.19 1.57 0
CT 415 106.23 1.61 -0.067 0.034 0.049
TT 103 95.74 1.69 -0.166 0.052 0.002
Per minor allele -0.078 0.024 0.001
HOMA insulin sensitivity (%) CC 362 74.06 1.63 0
CT 415 76.68 1.66 0.032 0.035 0.362
TT 103 82.80 1.55 0.110 0.054 0.043
Per minor allele 0.048 0.025 0.053
Cholesterol total mg/dL CC 379 212.92 1.21 0
CT 432 214.35 1.20 0.007 0.013 0.605
TT 109 208.83 1.21 -0.017 0.020 0.399
Per minor allele -0.004 0.009 0.680
LDL mg/dL CC 379 131.38 1.31 0
CT 432 132.27 1.29 0.008 0.018 0.670
TT 109 126.73 1.33 -0.033 0.028 0.251
Per minor allele -0.009 0.013 0.495
HDL mg/dL CC 379 52.55 1.29 0
CT 432 54.13 1.31 0.026 0.018 0.141
TT 109 56.32 1.30 0.072 0.027 0.009
Per minor allele 0.033 0.012 0.008
Triglycerides mg/dL CC 379 118.24 1.57 0
CT 432 113.5 1.58 -0.040 0.032 0.212
TT 109 102.65 1.56 -0.141 0.049 0.004
Per minor allele -0.061 0.022 0.006
BMI kg/m2 CC 356 27.75 4.06 0
CT 402 27.18 4.16 -0.532 0.292 0.069
TT 101 27.37 3.56 -0.347 0.451 0.442
Per minor allele -0.285 0.205 0.165
Waist Circumference cm CC 358 93.79 9.88 0
CT 409 91.93 10.66 -0.018 0.008 0.021
TT 99 91.35 10.24 -0.026 0.012 0.036
Per minor allele -0.015 0.006 0.009BMC Medicine 2006, 4:34 http://www.biomedcentral.com/1741-7015/4/34
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The waist circumference of those with the rs7903146 T
allele was significantly smaller (β = -0.0148, 95% CI -
0.0259 to 0.0037, p = 0.009). This association was little
changed by excluding those with diabetes or IFG (age and
sex adjusted per allele β = -0.0209, 95% CI -0.0334 to -
0.008, p = 0.001).
Characteristics of those with diabetes
The prevalence of diabetes was 12.4% in the CC group
and 18.9% in the TT group (Table 3); when combined
with ADA criteria-based IFG, the prevalences were 23.3%
and 32.4% respectively (per minor allele risk OR = 1.29,
95% CI 1.04 to 1.60, p = 0.023). There was a non-signifi-
cant trend to higher risks in the heterozygous group, pos-
sibly due to the limited sample size.
We next examined whether the characteristics of those
with diabetes varied by TCF7L2 status (Table 4). The TC
and TT groups were combined, owing to the small num-
bers. The T allele carrier patients with diabetes and the
wider group of patients with diabetes plus IFG were signif-
icantly less likely to have two or more ATP III-based fea-
tures[20] of metabolic syndrome (excluding
hyperglycemia), thus diabetic T allele carriers had an OR
= 0.37 (95% CI 0.15 to 0.92, p = 0.033) for metabolic syn-
drome as defined by the presence of hypertension,
abdominal obesity, high triglycerides and low HDL levels.
This included T allele carriers being markedly less likely to
have hypertension (OR-0.37, 95% CI 0.16 to 0.90, p =
0.028). Treating the relevant measures as continuous var-
iables showed the same pattern of associations.
There was no difference in the length of time that patients
had had diabetes (13.1 years in the CC group, 12.1 years
in the T carrier (CT/TT) group, p = 0.68). There was also
no significant association with treatment for diabetes:
59.2% in the CC group and 66.7% in the T group were on
some form of treatment (p = 0.393), although there was a
trend towards T allele carriers requiring more drug treat-
ment (p = 0.091) (60.1% on oral hypoglycemics or insu-
lin versus 44.9% in the CC group).
Numbers with complications were small (Table 4). How-
ever, we found suggestive evidence that T allele carriers are
less likely to have had a myocardial infarction, a key mac-
rovascular complication (for T carrier patients with diabe-
tes OR = 0.16, 95% CI 0.03 to 0.84, p = 0.030; for T carrier
patients with diabetes plus IFG OR = 0.27, 95% CI 0.08 to
0.92, p = 0.037). Conversely, T allele carriers were more
likely to have the key microvascular complication of poor
renal function, measured by 24-hour creatinine clearance
(T carrier patients with diabetes OR = 3.15, 95% CI 1.27
to 7.81, p = 0.013); this was also significant in linear mod-
els treating creatinine clearance as a continuous variable
(diabetes, β = -10.22, 95% CI -18.93 to -1.52, p = 0.022;
and combined β = -5.99, 95% CI -11.92 to -0.06, p =
0.048). Eleven of the 12 cases of retinopathy occurred in
the T carriers (CT/TT group) with diabetes (p = 0.067). A
further interesting finding was that 13 of the 14 cases of
physician-diagnosed dementia in the diabetes plus IFG
group were T allele carriers (p = 0.024), including all 10
cases of vascular dementia (chi2 p = 0.014).
Discussion
The TCF7L2 (rs7903146) polymorphism is the most pow-
erful single genetic variant influencing type 2 diabetes
risks identified to date[21]. In this study, we aimed to
explore the effects of this polymorphism in a general eld-
erly population, rather than in selected cases and controls.
We found that the TCF7L2 polymorphism is associated
with higher fasting glucose and lower insulin and
HOMA2b levels across this sample, suggesting beta-cell
impairment. Unexpectedly, however, we also found that
the rarer allele (T) is also associated with a more protective
Table 3: Prevalence of diabetes and impaired fasting glucose, plus logistic regression odds ratios by genotype
Age- and sex-adjusted ordinal logistic model
Condition Genotype Not case Case % OR 95% CI p value
Diabetes CC 345 49 12.44 1.00
CT 382 57 12.98 1.06 0.70–1.60 0.774
TT 90 21 18.92 1.64 0.93–2.87 0.085
Per minor allele 1.17 0.80–1.72 0.415
Impaired fasting glucose – ADA criteria (diabetics excluded) CC 355 39 9.90 1.00
CT 379 60 13.67 1.45 0.94–2.23 0.089
TT 96 15 13.51 1.42 0.75–2.69 0.279
Per minor allele 1.25 0.94–1.67 0.126
Diabetes or IFG (ADA) CC 306 88 23.34 1.00
CT 322 117 26.65 1.28 0.93–1.76 0.132
TT 75 36 32.43 1.67 1.05–2.65 0.031
Per minor allele 1.29 1.04–1.60 0.023BMC Medicine 2006, 4:34 http://www.biomedcentral.com/1741-7015/4/34
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lipid profile of higher HDL levels and lower triglyceride
levels. This latter finding was still significant after adjust-
ing for insulin resistance, suggesting that it is not second-
ary to the possible increase in insulin sensitivity that we
observed. The improved lipid profile was present even in
the population without diabetes or IFG (in whom a
smaller waist circumference was also found) and therefore
this finding is unlikely to be an artifact of TCF7L2 poly-
morphism carriers developing diabetes at lower levels of
abdominal obesity.
We also found that within the group of patients with dia-
betes and IFG, T allele carriers were less likely to have met-
abolic syndrome features (p  = 0.047) including
hypertension, or to have had a myocardial infarction (p =
0.037). This suggests a lower macrovascular risk factor
loading in the T allele group compared with the common
CC genotype. In contrast to the lower lipid risk profile,
however, T allele carriers with diabetes and IFG were more
likely to have certain microvascular-related complica-
tions, including poor renal function and perhaps a higher
rate of retinopathy. The association with physician diag-
noses of dementia in the T carriers with diabetes and IFG
was also unexpected, but may fit into the profile of raised
microvascular risk factors. The existence of an association
between dementia and diabetes was supported by a recent
systematic review[22].
The incidence of hypertension, macrovascular disease and
type 2 diabetes all increase with age[23], and prior to the
discovery of TCF7L2  it was suggested that a common
mechanism might be responsible for all of these patho-
logical states, as these conditions appear to cluster in the
same individuals. Patients with diabetes mellitus have a
much higher rate of cardiovascular disease (CVD) than
the general population, and dyslipidemia and other met-
abolic syndrome features seen in diabetes are accepted as
the major risk factors for CVD[24,25]. Clinical trials have
confirmed that lipid-lowering therapies result in a sub-
stantial reduction of cardiovascular risk in patients with
type 2 diabetes[26]. Our finding of lower rates of myocar-
dial infarction, although based on small numbers, is con-
sistent with patients with diabetes who carry the T allele
having a lower risk profile of metabolic-syndrome fea-
tures.
In contrast to macrovascular changes, diabetic microvas-
cular complications (including retinopathy[27], neuropa-
thy and nephropathy[28]) are mainly linked to
hyperglycemia[29]. Intensive blood-glucose control
decreases the risk of microvascular complications, but not
macrovascular disease, in patients with type 2 diabe-
tes[30]. Our finding of higher rates of microvascular com-
plications in T allele patients with diabetes is consistent
with specific dysfunction of insulin production in the beta
cell present with the TCF7L2 polymorphism[4], perhaps
leading to greater exposure to hyperglycemia-mediated
damage. The prevailing biochemical theories on how dia-
betes leads to microvascular disease[31] includes several
glucose-related pathways that contribute to endothelial
damage and dysfunction.
In evaluating these results, it is important to note that the
data are cross-sectional, and could perhaps have been
affected by differential survival of high-risk participants.
In theory, the lower risk lipid profile of T allele carriers
Table 4: Characteristics of patients with diabetes and ADA diagnosed hyperglycemia patients by TCF7L2 genotype
Diabetes Diabetes and impaired fasting glucose
Genotype n % Age- and sex-
adjusted OR
95% CI p value n % Age- and sex-
adjusted OR
95%CI p value
Two or more metabolic syndrome features CC 33 73.3 56 66.7
CT/TT 41 58.6 0.37 0.15–0.92 0.033 78 55.7 0.55 0.30–0.99 0.047
High blood pressure or anti-hypertension drugs CC 37 78.7 64 74.4
CT/TT 47 61.8 0.37 0.16–0.90 0.028 101 67.8 0.65 0.35–1.20 0.170
Abdominal obesity CC 25 54.4 44 51.8
CT/TT 35 49.3 0.53 0.20–1.35 0.180 67 46.9 0.67 0.36–1.22 0.188
High triglycerides CC 20 41.7 39 44.8
CT/TT 25 32.5 0.68 0.32–1.43 0.307 49 32.2 0.58 0.33–0.99 0.047
Low HDL levels CC 17 35.4 31 35.6
CT/TT 26 33.8 0.83 0.37–1.86 0.651 44 29 0.67 0.37–1.21 0.185
Myocardial infarction CC 7 14.6 8 9.2
CT/TT 2 2.6 0.16 0.03–0.84 0.030 4 2.6 0.27 0.08–0.92 0.037
Poor renal function (24-hour creatinine clearance) CC 12 26.1 31 36.9
CT/TT 32 47.1 3.15 1.27–7.81 0.013 69 49.3 1.74 0.96–3.17 0.066
Retinopathy reported CC 1 2.0 1 1.1
CT/TT 11 14.1 7.15 0.87–58.51 0.067 11 7.2 6.13 0.77–48.86 0.087
Dementia (physician diagnosed) CC 1 2.0 1 1.1
CT/TT 8 10.3 10.67 1.00–113.70 0.050 13 8.5 11.62 1.38–97.57 0.024
HDL, high-density lipoprotein.BMC Medicine 2006, 4:34 http://www.biomedcentral.com/1741-7015/4/34
Page 7 of 8
(page number not for citation purposes)
may be due to a markedly higher mortality rate in T carri-
ers who had had metabolic syndrome features plus the T
allele-associated diabetes risk, and therefore did not sur-
vive past 65 years of age. However, there was no signifi-
cant association between T allele status and age in this
study (linear sex adjusted regression β = 0.031, p = 0.963)
and there was also less dyslipidemia in the general popu-
lation, excluding those with diabetes or IFG, making a dif-
ferential mortality scenario less likely. A second limitation
is our relatively crude measure of beta-cell function; more
accurate measurements are obtained from oral glucose
tolerance tests, but these were not performed in InCHI-
ANTI. In addition, the numbers of patients with diabetes
with major complications are limited, and although the
findings presented are consistent with previous knowl-
edge of the mechanisms of diabetes-related complica-
tions, replication of these findings in independent
populations is clearly needed. Two-thirds of those with
diabetes were receiving some form of treatment, and prior
treatment may have influenced diabetes-specific esti-
mates, although rates of treatment were not significantly
different by SNP status. As treated patients with diabetes
are likely to have more severe disease and complications
than untreated patients, simple exclusion or adjustment
for treatment would be misleading. The presence of many
of the associations in the general population sample and
the combined diabetes and IFG groups, in which the effect
of treatment would be diluted, suggests that these findings
are robust.
If these findings are confirmed in other populations and
in prospective cohort studies, the presentation of T allele
carriers as having lower risk of metabolic syndrome but
greater risk of microvascular complications would have
obvious clinical implications. The desegregation of type 2
diabetes into subtypes with different patterns of risk sug-
gests that treatment approaches, especially to lipid reduc-
tion and closeness of glycemic control, could be more
closely tailored to genetic subtype.
Conclusion
The TCF7L2  polymorphism is associated with beta-cell
dysfunction but also a more protective lipid risk profile in
the general elderly population. TCF7L2 minor allele car-
rier patients with diabetes are less likely to have metabolic
syndrome features, but may be at higher risk from more
microvascular complications, including renal impairment
and (vascular) dementia. If replicated, these findings may
have implications for developing treatment approaches
tailored to the balance of risks in the different genotype
groups.
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